We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Actelion Agrees to Acquire Privately-Held Ceptaris Therapeutics

News   Aug 02, 2013

 
Actelion Agrees to Acquire Privately-Held Ceptaris Therapeutics
 
 
Advertisement
 

RELATED ARTICLES

Recreating Nature: Chemists Create Synthetic Version of Natural Anti-Cancer Agent

News

Scripps Research chemists Hans Renata, PhD, and Alexander Adibekian, PhD, have discovered a way to efficiently create a synthetic version of a valuable natural compound called cepafungin I, which has shown promise as an anti-cancer agent.

READ MORE

Wuhan COVID-19 Vaccine Trials Show Early Positive Results, Moving Forward to Phase 3 Testing

News

The adenovirus type-5-vectored COVID-19 vaccine was shown to be safe and induced significant immune responses in the majority of recipients after a single immunization.

READ MORE

Survey Highlights the Effects of COVID-19 Pandemic on Life Scientists

News

Jan Korbel and Oliver Stegle, both group leaders at EMBL Heidelberg, have performed a survey of fellow life scientists in Germany, Spain, the UK, Italy, France, Canada, Turkey, and the USA to learn how the current crisis, with partial or complete institutional shutdowns, is affecting their work.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE